FI102356B1 - Förfarande för framställning av ett antracyklin-ligandkonjugat - Google Patents

Förfarande för framställning av ett antracyklin-ligandkonjugat

Info

Publication number
FI102356B1
FI102356B1 FI902387A FI902387A FI102356B1 FI 102356 B1 FI102356 B1 FI 102356B1 FI 902387 A FI902387 A FI 902387A FI 902387 A FI902387 A FI 902387A FI 102356 B1 FI102356 B1 FI 102356B1
Authority
FI
Finland
Prior art keywords
anthracycline
ligand
conjugates
eliminated
methods
Prior art date
Application number
FI902387A
Other languages
English (en)
Finnish (fi)
Other versions
FI102356B (sv
FI902387A0 (fi
Inventor
Robert S Greenfield
Gary R Braslawsky
Lee J Olech
Takushi Kaneko
Peter A Kiener
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/353,729 external-priority patent/US5122368A/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of FI902387A0 publication Critical patent/FI902387A0/fi
Application granted granted Critical
Publication of FI102356B publication Critical patent/FI102356B/sv
Publication of FI102356B1 publication Critical patent/FI102356B1/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
FI902387A 1989-05-17 1990-05-14 Förfarande för framställning av ett antracyklin-ligandkonjugat FI102356B1 (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/353,729 US5122368A (en) 1988-02-11 1989-05-17 Anthracycline conjugates having a novel linker and methods for their production

Publications (3)

Publication Number Publication Date
FI902387A0 FI902387A0 (fi) 1990-05-14
FI102356B FI102356B (sv) 1998-11-30
FI102356B1 true FI102356B1 (sv) 1998-11-30

Family

ID=23390328

Family Applications (1)

Application Number Title Priority Date Filing Date
FI902387A FI102356B1 (sv) 1989-05-17 1990-05-14 Förfarande för framställning av ett antracyklin-ligandkonjugat

Country Status (19)

Country Link
EP (1) EP0398305B1 (sv)
JP (1) JP3062696B2 (sv)
KR (1) KR0136899B1 (sv)
AT (1) ATE150321T1 (sv)
AU (1) AU631638B2 (sv)
CA (1) CA2016584C (sv)
DE (1) DE69030213T2 (sv)
DK (1) DK0398305T3 (sv)
ES (1) ES2099075T3 (sv)
FI (1) FI102356B1 (sv)
GR (1) GR3023784T3 (sv)
HK (1) HK1005018A1 (sv)
IE (1) IE81109B1 (sv)
IL (1) IL94379A (sv)
MY (1) MY131039A (sv)
NO (1) NO300691B1 (sv)
NZ (1) NZ233696A (sv)
PT (1) PT94064B (sv)
ZA (1) ZA903757B (sv)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU638971B2 (en) * 1990-02-14 1993-07-15 Bristol-Myers Squibb Company Anthracycline immunoconjugates having a novel linker and methods for their production
CA2048089A1 (en) * 1990-09-17 1992-03-18 Wolfgang A. Wrasidlo Chemical conjugation of morpholino anthracyclines to antibodies
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
NZ337924A (en) * 1997-02-20 2002-09-27 Klaus Kimmeldirk Site-specific drug delivery compounds comprising an anchoring moiety, a linking group and a drug
US7033765B1 (en) 1997-02-20 2006-04-25 Toronto Research Chemicals, Inc. Site-specific drug delivery
GB9724838D0 (en) * 1997-11-26 1998-01-21 Franks Christopher R Compositions
WO2002000170A2 (en) * 2000-06-28 2002-01-03 Ward Page Faulk Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
WO2002049672A2 (en) * 2000-12-21 2002-06-27 Mcgill University Conjugates of antibodies and anticancer drugs
NZ511705A (en) * 2001-05-14 2004-03-26 Horticulture & Food Res Inst Methods and rapid immunoassay device for detecting progesterone and other steroids
KR100507968B1 (ko) * 2001-08-18 2005-08-17 한국과학기술연구원 자기집합체를 형성하는 항암제-키토산 복합체 및 그의제조방법
WO2004093807A2 (en) 2003-04-22 2004-11-04 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Somatostatin vectors
EP1680073B1 (en) * 2003-10-21 2013-01-02 IGF Oncology, LLC Compounds and method for treating cancer
US9011880B2 (en) 2003-10-21 2015-04-21 Igf Oncology, Llc Compounds and methods for treating cancer
WO2005084390A2 (en) * 2004-03-02 2005-09-15 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
EP1695717A1 (en) * 2005-02-23 2006-08-30 Ludwig-Maximilians-Universität Transport of nano-and macromolecular structures into cytoplasm and nucleus of cells
AU2009270988A1 (en) * 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
US9675671B2 (en) 2014-01-12 2017-06-13 Igf Oncology, Llc Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
EP3191134B1 (en) * 2014-09-12 2019-11-20 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
CA3059593A1 (en) 2017-05-21 2018-11-29 Igf Oncology, Llc An insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957755A (en) * 1967-10-18 1976-05-18 Rhone-Poulenc S.A. Naphthacene derivatives
US4112217A (en) * 1977-09-02 1978-09-05 Sri International Bis-hydrazones of daunomycin and adriamycin
US4263428A (en) * 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US5162512A (en) * 1982-03-09 1992-11-10 Cytogen Corporation Amine derivatives of anthracycline antibodies
US4950738A (en) * 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics
GB8610551D0 (en) * 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
AU638971B2 (en) * 1990-02-14 1993-07-15 Bristol-Myers Squibb Company Anthracycline immunoconjugates having a novel linker and methods for their production

Also Published As

Publication number Publication date
CA2016584A1 (en) 1990-11-17
CA2016584C (en) 1999-06-29
EP0398305B1 (en) 1997-03-19
JPH0327321A (ja) 1991-02-05
IL94379A (en) 1997-02-18
ATE150321T1 (de) 1997-04-15
NO300691B1 (no) 1997-07-07
KR0136899B1 (ko) 1998-04-25
DK0398305T3 (da) 1997-06-23
HK1005018A1 (en) 1998-12-18
FI102356B (sv) 1998-11-30
NO902197D0 (no) 1990-05-16
DE69030213T2 (de) 1997-10-16
ZA903757B (en) 1992-01-29
DE69030213D1 (de) 1997-04-24
AU631638B2 (en) 1992-12-03
AU5511790A (en) 1990-11-22
NO902197L (no) 1990-11-19
JP3062696B2 (ja) 2000-07-12
KR900017597A (ko) 1990-12-19
PT94064A (pt) 1991-01-08
PT94064B (pt) 1997-07-31
IE81109B1 (en) 2000-03-08
GR3023784T3 (en) 1997-09-30
ES2099075T3 (es) 1997-05-16
EP0398305A3 (en) 1991-03-20
MY131039A (en) 2007-07-31
FI902387A0 (fi) 1990-05-14
NZ233696A (en) 1992-04-28
IL94379A0 (en) 1991-03-10
EP0398305A2 (en) 1990-11-22
IE901764L (en) 1990-11-17

Similar Documents

Publication Publication Date Title
IL106992A0 (en) Acylhydrazone derivatives of anthracycline and methods for their preparation
FI102356B1 (sv) Förfarande för framställning av ett antracyklin-ligandkonjugat
US5514794A (en) Antibody-drug conjugates
JPH08509698A (ja) 蛋白質複合体、それを含む組成物及びその医薬としての用途
CA2010164A1 (en) Anthracycline immunoconjugates having a novel linker and methods for their production

Legal Events

Date Code Title Description
FG Patent granted

Owner name: BRISTOL-MYERS SQUIBB COMPANY